


## N-Desmethyl dosimertinib-d<sub>5</sub>

<b>Cat. No.:</b>	HY-142283BS
<b>CAS No.:</b>	2719691-00-4
<b>Molecular Formula:</b>	C <sub>27</sub> H <sub>26</sub> D <sub>5</sub> N <sub>7</sub> O <sub>2</sub>
<b>Molecular Weight:</b>	490.61
<b>Target:</b>	EGFR
<b>Pathway:</b>	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	N-Desmethyl dosimertinib-d <sub>5</sub> is the deuterium labeled <a href="#">Dosimertinib</a> (HY-142283). Dosimertinib is a highly potent, selective, and orally active deuterated EGFR inhibitor. Dosimertinib can be used for the research of non-small-cell lung cancer[1][2].
<b>In Vitro</b>	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

- [1]. Yonggang Meng, et al. Discovery of Dosimertinib, a Highly Potent, Selective, and Orally Efficacious Deuterated EGFR Targeting Clinical Candidate for the Treatment of Non-Small-Cell Lung Cancer. *J Med Chem*. 2021 Jan 28;64(2):925-937.
- [2]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother*. 2019;53(2):211-223.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA